Vertex/CRISPR VCTX211 (CRISPR hypoimmune islets)

VCTX211 is a "cloak, don't cage" attempt at a drug-free cure for type 1 diabetes. It combines two technologies: lab-grown insulin-producing islet cells (made from a stem-cell line, called PEC211 pancreatic endoderm cells) and CRISPR-Cas9 gene editing that rewrites those cells to be "hypoimmune" — engineered so the immune system is far less able to see and destroy them.¹² The goal is a transplant that survives without the lifelong immunosuppressant drugs that today's islet transplants require.³

How the cloaking works. The cells are edited to remove the surface flags (HLA class I, via knockout of the B2M gene) that the immune system reads as "foreign," and to add molecules that actively calm immune cells — including PD-L1 and HLA-E, plus survival-boosting edits (TNFAIP3, MANF) and a metabolic tweak (TXNIP knockout).⁴ This builds on a well-published "hypoimmune" concept: removing HLA and over-expressing a "don't-eat-me" signal lets edited cells evade rejection in animal models and, in related cell-therapy programs, in people.⁵⁶ As a belt-and-braces measure, VCTX211 is also loaded into a small, removable, perforated pouch implanted under the skin, so the graft can be retrieved if needed.¹²

The lineage. VCTX211 is the second generation. Its predecessor, VCTX210 (B2M knockout plus PD-L1), was a proof-of-concept; VCTX211 added "novel edits to promote cell survival," and a third-generation candidate, VCTX212, remains in preclinical work.⁴⁷

Clinical evidence. A first-in-human, open-label Phase 1 study (NCT05565248) ran at two Canadian sites, enrolling adults aged 18-65 who had lived with T1D for at least five years.³ Crucially, chronic immunosuppression was an exclusion criterion — confirming the immunosuppression-free design.³ The trial was meant to measure safety plus C-peptide (a marker of the body's own insulin), insulin use, hypoglycemia, HbA1c, time-in-range, graft immune infiltration, and new anti-graft antibodies.³ However, the study was terminated (primary completion August 2025) with only 5 participants, the sponsor stating patients would be "followed up in the VCTX-201 study."³ No efficacy results — no insulin-independence or C-peptide figures — have been published, so its effectiveness in people is genuinely unknown.³

Corporate twists matter here. The program came from ViaCyte (acquired by Vertex in 2022) and CRISPR Therapeutics; in March 2023 Vertex paid $100 million up front (up to $230 million in milestones) for rights to the hypoimmune technology.⁸⁹ In January 2024 Vertex ended the diabetes collaboration, leaving CRISPR Therapeutics to develop the asset alone, now branded CTX211.¹⁰ (Note: two 2024 patient deaths that made headlines were in Vertex's separate VX-880/zimislecel trial, not VCTX211.)¹⁰

Safety and durability. The retrievable device is a deliberate safety feature, and editing raises standard concerns about off-target effects and uncontrolled growth — but no VCTX211-specific safety problems were reported.¹⁵ Durability against both rejection and the original autoimmunity is the central open question and was never read out.³

What's coming. VCTX211 itself appears wound down as a standalone trial; its real legacy is as a stepping stone. CRISPR Therapeutics now owns the platform and has signaled intent to keep advancing immunosuppression-free, gene-edited islet replacement, with VCTX212 as the next-generation candidate.⁷¹⁰ The bigger picture: the hypoimmune "cloak" strategy is being pursued across the field (e.g., Sana Biotechnology's B2M/CIITA-knockout, CD47-overexpressing cells), so even if this specific product fades, the approach it pioneered is very much alive.⁴⁶

References

References

1. ClinicalTrials.gov. An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (NCT05565248). U.S. National Library of Medicine (2023–2026). https://clinicaltrials.gov/study/NCT05565248 ↩ ↩² ↩³

2. CRISPR Medicine News. Clinical trial: Type 1 Diabetes (NCT05565248) — VCTX211 allogeneic gene-edited PEC211 cells plus durable, removable perforated device. CRISPR Medicine (2023). https://crisprmedicinenews.com/clinical-trial/type-1-diabetes-t1d-nct05565248/ ↩ ↩²

3. ClinicalTrials.gov. NCT05565248 record — status TERMINATED, 5 participants, primary completion 2025-08-08, reason "Patients to be followed up in the VCTX-201 study"; eligibility (T1D ≥5 years, ages 18-65, chronic immunosuppression excluded) and outcome measures (C-peptide, insulin use, HbA1c, time-in-range, anti-graft antibodies). U.S. National Library of Medicine (accessed 2026). https://clinicaltrials.gov/study/NCT05565248 ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

4. Technology Networks. Gene-Edited Stem Cell-Derived Therapies — A Functional Cure for T1D? (VCTX210: B2M knockout + PD-L1; VCTX211: B2M and TXNIP knockouts plus PD-L1, HLA-E, TNFAIP3 and MANF insertions). Technology Networks (2024). https://www.technologynetworks.com/biopharma/blog/gene-edited-stem-cell-derived-therapies-a-functional-cure-for-t1d-357837 ↩ ↩² ↩³

5. Hu X, Manner K, DeJesus R, et al. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice (B2M/CIITA/TRAC knockout + CD47 over-expression; CD47-targeting safety strategy). Nature Communications (2023). https://doi.org/10.1038/s41467-023-37785-2 ↩ ↩²

6. Hu X, Beauchesne P, Wang C, et al. Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease (clinical evidence that HLA-depleted, CD47-overexpressing cells avoid alloimmune attack). Cell Stem Cell (2025). https://doi.org/10.1016/j.stem.2025.07.009 ↩ ↩²

7. Patsnap Synapse. VCTX-212 drug profile — third hypoimmune stem-cell program for type 1 (and type 2) diabetes, in preclinical development; VCTX211 includes novel edits to promote cell survival and was cleared by Health Canada in late 2022. Patsnap Synapse (accessed 2026). https://synapse.patsnap.com/drug/8f62bcd2c5e342f5aa793d93c3f65952 ↩ ↩²

8. CRISPR Therapeutics. CRISPR Therapeutics and Vertex Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes (March 27, 2023; $100M upfront, up to $230M milestones plus royalties; VCTX211 Phase 1/2 ongoing). CRISPR Therapeutics (2023). https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-and-vertex-announce-licensing-agreement-to-accelerate-development-of-vertexs-hypoimmune-cell-therapies-for-the-treatment-of-type-1-diabetes ↩

9. Pharmaceutical Technology. Vertex signs licence deal with CRISPR for diabetes therapies ($100m upfront, up to $230m in R&D milestones; VCTX211 Phase I/II ongoing; hypoimmune islet cells for T1D). Pharmaceutical Technology (2023). https://www.pharmaceutical-technology.com/news/vertex-crispr-diabetes-therapies/ ↩

10. Pharma Manufacturing. Vertex axes diabetes cell therapy deal with CRISPR (collaboration ended early 2024; CRISPR Therapeutics takes sole responsibility for CTX211 / formerly VCTX211, an immunosuppression-free beta-cell replacement). Pharma Manufacturing (2024). https://www.pharmamanufacturing.com/industry-news/news/33017292/vertex-axes-diabetes-cell-therapy-deal-with-crispr ↩ ↩² ↩³